GlycoVaxyn has developed a proprietary recombinant DNA technology that for the first time enables the in vivo synthesis of novel and well characterized immunogenic polysaccharide/protein complexes for use in vaccines in an efficient and cost-effective manner. The technology utilizes validated and well understood recombinant DNA techniques along with patented genes to produce "natural" carbohydrate-protein conjugates or bioconjugates that can be used as vaccines. GlycoVaxyn's bioconjugates can produce functional antibodies that protect against diseases in animal models.
In GlycoVaxyn's patented process, the gene cluster responsible for the biosynthesis of the bacterial LPS, capsule polysaccharide (CPS) or oligo polysaccharides (oligo PS) is transformed into E. coli together with the protein carrier of interest along with GlycoVaxyn's patented enzyme that performs the bioconjugation reaction in vivo. Once produced upon induction, simple purification steps are performed and the biological products are formulated for use as a vaccine. The process of recombinant bioconjugation preserves the bacterial carbohydrate's and protein's native structure and only produces specific conjugates with a known number of conjugated components. This process yields highly reproducible batches.
The key advantages of GlycoVaxyn's technology platform are:
The technology has broad potential applications in the field of bacterial vaccines but also in viral and cancer vaccines and human therapeutic proteins.
Available conjugate vaccines are developed and manufactured by employing a chemical conjugation process.
